Oncology Response
Tumor response assessment frameworks for CT, MRI and PET.
Assigns the RECIST 1.1 overall response category (CR, PR, SD or PD) for a single follow-up time point from the change in the sum of target-lesion diameters, the non-target lesion status and the presence of new lesions.
Applies the modified RECIST criteria for hepatocellular carcinoma, in which only the arterially enhancing (viable) portion of each target lesion is measured, to categorize response as CR, PR, SD or PD.
Evaluates gastrointestinal stromal tumor response to tyrosine-kinase inhibitors using both tumor size and CT attenuation, classifying the examination as CR, PR, SD or PD by the Choi criteria.
Applies iRECIST (Seymour 2017) to solid-tumor immunotherapy assessments. Apparent progression or new lesions first score as unconfirmed progressive disease (iUPD); confirmed progressive disease (iCPD) requires repeat imaging 4-8 weeks later showing further increase in tumor burden or worsening/new lesions. New lesions are measured in a separate sum and are not added to the original target-lesion sum.
Assigns CR, PR, SD, or PD for high-grade glioma using classic RANO (Wen 2010) rules: bidimensional sum of products of perpendicular diameters (SPD) of measurable enhancing disease, plus T2/FLAIR trend, corticosteroid dose, clinical status, and new lesions. Notes how RANO 2.0 (2023) changes baseline timing, confirmation of early PD, volumetrics, and use of non-enhancing disease.